Kasherman Lawrence, Garg Swati, Tchrakian Nairi, Clarke Blaise, Karakasis Katherine, Kim Raymond H, Stockley Tracy L, Dhani Neesha, Oza Amit M, Lheureux Stephanie
Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
• variant negative high-grade serous ovarian cancer is rare and can still show p53 abnormal immunohistochemistry.•Diagnostic and therapeutic considerations include pathologic, molecular and clinical domains.•Genetic reassessment through more comprehensive assays should be considered to ensure no missed rare or complex variants.•Presence of mutations can occur in variant high-grade serous ovarian cancer.
• 变异阴性的高级别浆液性卵巢癌很罕见,但仍可显示p53免疫组化异常。
• 诊断和治疗考量包括病理学、分子学和临床领域。
• 应考虑通过更全面的检测进行基因重新评估,以确保不遗漏罕见或复杂变异。
• 变异型高级别浆液性卵巢癌中可出现突变。